SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical
company pioneering a novel disease-modifying therapeutic approach to
treat a key underlying cause of Alzheimer’s and other degenerative
diseases, today announced that it has priced its initial public offering
of 4,412,000 shares of its common stock at a price to the public of
$17.00 per share, before underwriting discounts and commissions. In
addition, Cortexyme has granted the underwriters a 30-day option to
purchase up to an additional 661,800 shares at the initial public
offering price, less the underwriting discounts and commissions. All of
the shares of common stock are being offered by Cortexyme. The shares
are expected to begin trading on the Nasdaq Global Select Market on May
9, 2019 under the ticker symbol “CRTX.” The offering is expected to
close on May 13, 2019, subject to customary closing conditions.
BofA Merrill Lynch and Credit Suisse Securities (USA) LLC are acting as
joint book-running managers for the proposed offering. Canaccord Genuity
LLC and JMP Securities LLC are acting as co-managers.
The offering is being made only by means of a prospectus. Copies of the
final prospectus relating to this offering may be obtained from any of
the following sources:
-
BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd
Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or
by phone at 1-800-294-1322 or by email at dg.prospectus_requests@baml.com; -
Credit Suisse Securities (USA) LLC, Attn: Prospectus Department,
Eleven Madison Avenue, 3rd Floor, New York, NY 10010, by telephone at
1-800-221-1037 or by email at usa.prospectus@credit-suisse.com.
A registration statement relating to these securities has been filed
with the Securities and Exchange Commission and was declared effective
on May 8, 2019. This press release shall not constitute an offer to sell
or the solicitation of an offer to buy, nor shall there be any sale of
shares of Cortexyme’s common stock in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or jurisdiction.
About Cortexyme, Inc.
Cortexyme is a clinical stage pharmaceutical company pioneering a novel
disease-modifying therapeutic approach to treat a key underlying cause
of Alzheimer’s disease and other degenerative diseases. Cortexyme is
targeting a specific, infectious pathogen found in the brain of
Alzheimer’s patients and tied to neurodegeneration and neuroinflammation
in animal models. The company’s lead investigational medicine, COR388,
is the subject of the GAIN Trial, an ongoing Phase 2/3 clinical study in
patients with mild to moderate Alzheimer’s.
Forward-Looking Statements
Statements in this press release contain “forward-looking statements”
that are subject to substantial risks and uncertainties. Forward-looking
statements contained in this press release may be identified by the use
of words such as “anticipate,” “expect,” “believe,” “will,” “may,”
“should,” “estimate,” “project,” “outlook,” “forecast” or other similar
words, and include, without limitation, statements regarding Cortexyme’s
expectations regarding the commencement of trading of its shares on the
Nasdaq Global Select Market, the completion and timing of the closing of
the offering. Forward-looking statements are based on Cortexyme’s
current expectations and are subject to inherent uncertainties, risks
and assumptions that are difficult to predict. Further, certain
forward-looking statements are based on assumptions as to future events
that may not prove to be accurate. Factors that could cause actual
results to differ include, but are not limited to, risks and
uncertainties related the satisfaction of customary closing conditions
related to, and the completion of, the public offering. These and other
risks and uncertainties are described more fully in the section titled
“Risk Factors” in the final prospectus related to the public offering to
be filed with the Securities and Exchange Commission. Forward-looking
statements contained in this announcement are made as of this date, and
Cortexyme undertakes no duty to update such information except as
required under applicable law.
Contacts
Chris Lowe
Chief Financial Officer
Cortexyme, Inc.
clowe@cortexyme.com
Hal Mackins
For Cortexyme, Inc.
hal@torchcomllc.com
(415)
994-0040